- Home
- LXEO vs DPG Comparison
LXEO vs DPG Comparison
Compare LXEO & DPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | LXEO | DPG |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Trusts Except Educational Religious and Charitable |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 486.1M | 535.3M |
| IPO Year | 2023 | 2011 |
Fundamental Metrics
Financial Performance| Metric | LXEO | DPG |
|---|---|---|
| Price | $5.44 | $14.32 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $18.60 | N/A |
| AVG Volume (30 Days) | ★ 735.5K | 86.6K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $654,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.45 | $10.45 |
| 52 Week High | $10.99 | $14.96 |
Technical Indicators
Market Signals| Indicator | LXEO | DPG |
|---|---|---|
| Relative Strength Index (RSI) | 31.25 | 50.08 |
| Support Level | $4.93 | $14.04 |
| Resistance Level | $7.77 | $14.81 |
| Average True Range (ATR) | 0.44 | 0.25 |
| MACD | -0.07 | -0.04 |
| Stochastic Oscillator | 10.22 | 37.18 |
Price Performance
Historical ComparisonAbout LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
About DPG Duff & Phelps Utility and Infrastructure Fund Inc.
Duff & Phelps Utility & Infrastructure Fund Inc. is an investment fund, and its objective is to seek total return, derived mainly from a high level of current income, with an emphasis on providing tax-advantaged dividend income and growth in current income, and secondarily from capital appreciation.